Testing Utility of Commercially Available Sleep Trackers for Physician-Patient Communication

Sponsor
Regenstrief Institute, Inc. (Other)
Overall Status
Unknown status
CT.gov ID
NCT03795129
Collaborator
Merck Sharp & Dohme LLC (Industry), National Sleep Foundation (Other)
200
1
2
8.6
23.1

Study Details

Study Description

Brief Summary

Sleep related disorders are common in primary care practice. Sleep wear related data has not been utilized to improve sleep related communication between patients and providers. The study team is conducting a randomized study to improve physical-patient communication regarding sleep through a novel intervention based upon sleep wear and the SleeplifeĀ® app.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: SleepLife Application w/FitBit
  • Behavioral: FitBit w/Minimal to No SleepLife App.
N/A

Detailed Description

Based on a National US survey in 2012, 69% adults track at least one health indicator using either a tracking device or some other means. The main health indicators tracked were diet, weight, and exercise. Although not as extensive as the above health indicators, certain studies also looked at sleep indicators through the trackers to support validity of their use. Based on the study team's literature review, none of the studies looked at an intervention designed to utilize data-trackers-based data to improve physician-patient communication regarding sleep.

Commercially available and inexpensive exercise, fitness and sleep trackers are broadly available and consumer use is growing rapidly. Industry analysts estimate that over 30 million Americans have access to their sleep tracking data (e.g. Fitbit. Jawbone). Physicians seldom use patient-generated (i.e. subjective) sleep data (e.g. sleep diaries) and have been slow to integrate objective sleep data collected from commercial sleep trackers. Two commercial sleep trackers have been validated by independent testing. The National Sleep Foundation (NSF) has led recent efforts to establish normative data (i.e. appropriate ranges) for sleep duration and sleep quality. NSF, together with the Consumer Electronics Association (now Consumer Technology Association), has established a work-group involving over 40 sleep tracking technology companies which is working to standardize sleep tracking data collection and reporting. Finally, NSF has developed a tool ("SleepLife") that translates data retrieved from all commercially available sleep trackers into a personal sleep tracking record. This product has been tested rigorously for two years and publicly released in January 2016. These developments present the timely opportunity to test a new paradigm for patient and physician communication using objective patient data (sleep).

The study team will utilize a combination of observational and interventional study designs to achieve study objectives.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
200 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a cluster randomized trial that is randomized at the clinic level.This is a cluster randomized trial that is randomized at the clinic level.
Masking:
None (Open Label)
Masking Description:
Masking will not occur.
Primary Purpose:
Health Services Research
Official Title:
Testing Utility of Commercially Available Sleep Trackers for Physician-Patient Communication Around Sleep Experience, Habits, and Behaviors
Actual Study Start Date :
Jun 10, 2018
Anticipated Primary Completion Date :
Dec 31, 2018
Anticipated Study Completion Date :
Feb 28, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: SleepLife Application w/FitBit

Subject receives a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application. Subject physicians will receive subject sleep data. Subject and physicians have the option of messaging each other through the SleepLife application.

Behavioral: SleepLife Application w/FitBit
Subjects receive a FitBit. Subjects receive access to the SleepLife Application. Subjects receive training and assistance setting up use and access to the SleepLife Application. Subjects' physicians will receive subject sleep data. Subjects and physicians have the option of messaging each other through the SleepLife application.

Active Comparator: FitBit w/Minimal to No SleepLife App.

Subjects will receive a FitBit Subjects will be told about the SleepLife Application (but not be shown how to access it). Subjects will receive no training with regard to how to access SleepLife Application. Subjects' physicians will receive no subject sleep data.

Behavioral: FitBit w/Minimal to No SleepLife App.
Subjects will receive a FitBit. Subjects will be told about the SleepLife Application (but not be shown how to access it). Subjects will receive no training with regard to how to access SleepLife Application. Subjects' physicians will receive no subject sleep data.

Outcome Measures

Primary Outcome Measures

  1. Number of physicians using a commercially available sleep tracker assessed by the "Physician Satisfaction/Communication" questionnaire who saw an improvement in physician-patient dialogue regarding sleep and related behaviors and habits [Six Months]

    For patient-physician communications from the physicians' end, the team will collect all scores, ranging from 1 to 5, for all the "Communication" questions in the "Physician Satisfaction/Communication" questionnaire. The scores will be summed up as the total communication score from physician, and the total score will be treated as continuous response variable. Then a binary variable indicating whether the physician is in the intervention (=1) or control (=0) arm will be treated as the main explanatory variable, a continuous variable regarding the time where the measurements are recorded, and the set of general demographic variables (age, race, gender, etc) will be used as covariates. We will use linear regression model, and select relevant variables using Bayesian information criterion (BIC) in a step-wise manner. The SleepLife app will be pulling time-to-sleep (TST), amount of time in minutes to sleep, number of awakenings greater than 5 minutes, and sleep efficiency.

  2. Number of patient-physician communicationdialog assessed by using a commercially available sleep tracker assessed by the "Patient Satisfaction" questionnaire. [Six Months]

    For patient-physician communications from the patients' end, the team will collect all the scores, ranging from 1 to 5, for all the "Communication" questions in the "Patient Satisfaction" questionnaire. The scores will be summed up as the total communication score from the patients' end, and the total score will be treated as continuous response variable. Then a binary variable indicating whether the patient is in the intervention (=1) or control (=0) arm will be treated as the main explanatory variable, a continuous variable regarding the time where the measurements are recorded, and the set of general demographic variables (age, race, gender, etc) will be used as covariates. Considering the linear responses and the cluster design, the team will use generalized estimating equation (GEE) model with an identity link function, and the team will select relevant variables using QIC in a step-wise manner.

Secondary Outcome Measures

  1. Number of physician subjects with satisfaction with sleep counseling that improves when presented with objective patient sleep data. [Six Months]

    For physicians' satisfactory score, the team will collect all the scores, ranging from 1 to 5, for all the "GS" questions in the "Physician Satisfaction/Communication" questionnaire. The scores will be summed up as the total physicians' satisfaction score, and the total score will be treated as continuous response variable. Then a binary variable indicating whether the physician is in the intervention (=1) or control (=0) arm will be treated as the main explanatory variable, a continuous variable regarding the time where the measurements are recorded, and the set of general demographic variables (age, race, gender, etc) will be used as covariates. The team will use linear regression model, and select relevant variables using BIC in a step-wise manner.

  2. Number of patients who feel that their communication with their physician has improved as a result of the program as measured by the "Patient Satisfaction" survey. [Six Months]

    For patients' satisfaction, the team will collect all scores, ranging from 1 to 5, for all the "General Satisfaction" questions in the "Patient Satisfaction" questionnaire. These scores will be summed up as the total patients' satisfaction score for the treatment and interaction with the physician, as a result of the program. Then a binary variable indicating whether the patient is in the intervention (=1) or control (=0) arm will be treated as the main explanatory variable, a continuous variable regarding the time where the measurements are recorded, and the set of general demographic variables (age, race, gender, etc) will be used as covariates. Considering the linear responses and the cluster design, the team will use GEE model with an identity link function, and we will select relevant variables using QIC in a step-wise manner.

Other Outcome Measures

  1. To determine if data improves over time for measures related to total sleep time (TST) and satisfaction with sleep. [Six Months]

    the team will collect all the scores, ranging from 0 to 100, for all the "Sleep Outcomes" questions in the sleep outcome questionnaire. These scores will be summed up as the total patients' sleep outcomes. Then a binary variable indicating whether the patient is in the intervention (=1) or control (=0) arm will be treated as the main explanatory variable, a continuous variable regarding the time where the measurements are recorded, and the set of general demographic variables (age, race, gender, etc) will be used as covariates. Considering the linear responses and the cluster design, we will use GEE model with an identity link function, and we will select relevant variables using QIC in a step-wise manner.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. 18 and older

  2. Have insomnia as identified by electronic record and/or a validated questionnaire

  3. Prescription medication for insomnia with International Classification of Disease (ICD) codes: 327., 780.5, 347.; icd-10's G47 and medications: Ambien (zolpidem), Belsomra (suvorexant), Butisol (butabarbital), Doral (quazepam), Edluar (zolpidem), Estazolam, Flurazepam, Halcion (triazolam), Hetlioz (tasimelteon), Intermezzo (zolpidem), Lunesta (eszopiclone), Restoril (temazepam), Rozerem (ramelteon), Seconal (secobarbital), Silenor (doxepin), Sonata (zaleplon), and Zolpimist (zolpidem)

  4. English speaking 4. Consentable in-person 5. Have access to a telephone with smart phone capabilities. (iOS/Android)

Exclusion Criteria:
  1. Not English speaking

  2. Have ischemic or hemorrhagic cerebrovascular disease affecting collection of study outcomes (via ICD codes I6*, 43*)

  3. History of dementia (via ICD codes F0*, 290*)

  4. History of Bipolar/Schizophrenia/Depression (via ICD codes F2*, F31*, 296*, 295*)

  5. History of alcohol or substance abuse (via ICD codes F1*, 304*, 303*)

  6. Incarcerated/Long Term Care (LTC)

  7. Unable to complete study questionnaires due to hearing loss or blindness

Contacts and Locations

Locations

Site City State Country Postal Code
1 Regenstrief Institute Indianapolis Indiana United States 46202

Sponsors and Collaborators

  • Regenstrief Institute, Inc.
  • Merck Sharp & Dohme LLC
  • National Sleep Foundation

Investigators

  • Principal Investigator: Babar Khan, MD, Regenstrief Institute, Inc.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Regenstrief Institute, Inc.
ClinicalTrials.gov Identifier:
NCT03795129
Other Study ID Numbers:
  • Merck - 34
First Posted:
Jan 7, 2019
Last Update Posted:
Jan 7, 2019
Last Verified:
Jan 1, 2019
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Regenstrief Institute, Inc.
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 7, 2019